Skip to main content

Metastatic Renal Cell Cancer: An Analysis of Reimbursement Decisions

Advances in Therapy volume 36, pages 1266–1278 (2019)Cite this article

Abstract

Introduction

Metastatic renal cell carcinoma is a complex cancer for which several drugs have been developed over the years. More recently, drugs that target the specific cancer cell mutations have been developed for metastatic cell carcinoma. However, even with the recent influx of targeted therapy options, significant unmet needs exist in around half of treated renal cell carcinoma patients following the failure of first-line therapy. The aim of this study was to review the health technology appraisals of renal cell carcinoma treatments in several countries to establish what factors might affect the reimbursement decisions.

Methods

The reimbursement data for 10 drugs in several countries were collated from the health technology assessment bodies for each country. The data included information on clinical trials used in the submission documents for the health technology assessment, the reimbursement decisions and the reasons for those decisions, as well as any specific restrictions for use of any of the included drugs.

Results

Of the 10 drugs reviewed, only everolimus received a positive reimbursement decision by all the health technology assessment bodies included in the study. The most common reason for a negative reimbursement decision was lack of demonstration of cost-effectiveness of the drugs. Another frequently cited reason was unproven clinical efficacy and poor impact on overall survival.

Conclusion

Despite the many treatment guidelines and current treatment options that are available for renal cell carcinoma, there remains an unmet need in patients with metastatic renal cell carcinoma. On the basis of this analysis, the key reason for a drug not obtaining a positive reimbursement decision is due to poor efficacy or uncertainty of the drug’s efficacy.

Funding

Eisai, Inc.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

Abbreviations

BSC:

Best supportive care

CADTH:

Canadian Agency for Drugs and Technologies in Health

ECOG:

Eastern Cooperative Oncology Group

ESMO:

European Society for Medical Oncology

G-BA:

Federal Joint Committee (Gemeinsamer Bundesausschuss)

HAS:

Haute Autorité de Santé

HTA:

Health Technology Assessment

IL-2:

Interleukin 2

IQWiG:

Institute for Quality and Efficiency in Healthcare

mRCC:

Metastatic renal cell carcinoma

MSKCC:

Memorial Sloan Kettering Cancer Center

mTOR:

Mammalian target of rapamycin

NCCN:

National Comprehensive Cancer Network

NICE:

National Institute for Health and Care Excellence

OS:

Overall survival

PAS:

Patient access scheme

PBAC:

Pharmaceutical Benefits Advisory Committee

PBS:

Pharmaceutical Benefits Scheme

pCODR:

pan-Canadian Oncology Drug Review

PD-1:

Programmed cell death-1

RCC:

Renal cell carcinoma

RECIST:

Response Evaluation Criteria In Solid Tumours

SMC:

Scottish Medicines Consortium

TGA:

Therapeutic Goods Administration

TKI:

Tyrosine kinase inhibitors

TLV:

Tandvårds-och läkemedelsförmånsverket

VEGF:

Vascular endothelial growth factor

WHO:

World Health Organisation

References

  1. Ljungberg B, Bensalah K, Bex A, et al. Guidelines on renal cell carcinoma. 2014. https://uroweb.org/wp-content/uploads/10-Renal-Cell-Carcinoma_LR.pdf. Accessed Nov 2017.

  2. Cairns P. Renal cell carcinoma. Cancer Biomark. 2011;9(1–6):461–73.

    Article  CAS  PubMed Central  Google Scholar 

  3. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193–205. https://doi.org/10.1016/j.ctrv.2007.12.001.

    Article  PubMed  Google Scholar 

  4. Cancer Research Institute. Immunotherapy for kidney cancer. 2017. https://www.cancerresearch.org/we-are-cri/home/cancer-types/kidney-cancer. Accessed Nov 2017.

  5. Kirner A, Mayer-Mokler A, Reinhardt C. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Human Vacc Immunother. 2014;10(11):3179–89. https://doi.org/10.4161/21645515.2014.983857.

    Article  Google Scholar 

  6. National Cancer Institute. SEER stat fact sheets: kidney and renal pelvis cancer. 2015. https://seer.cancer.gov/statfacts/html/kidrp.html. Accessed Nov 2017.

  7. Campbell MT, Jonasch E. Updates in the systemic treatment of patients with metastatic renal cell carcinoma. https://gucasym.org/daily-news/updates-systemic-treatmentpatients-metastatic-renal-cell-carcinoma. Accessed Nov 2017.

  8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology—kidney cancer. 2017. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308682/. Accessed Nov 2017.

  9. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58–68. https://doi.org/10.1093/annonc/mdw328.

    Article  CAS  PubMed  Google Scholar 

  10. Canadian Agency for Drugs and Technology (CADTH). https://www.cadth.ca/.

  11. Haute Autorité de Santé (HAS). https://www.has-sante.fr/portail/. Accessed Nov 2017.

  12. Gemeinsamer Bundesausschuss (G-BA). https://www.g-ba.de/. Accessed Nov 2017.

  13. Institute for Quality and Efficiency in Health Care (IQWiG). https://www.iqwig.de/en/home.2724.html. Accessed Nov 2017.

  14. Tandvårds- och läkemedelsförmånsverket (TLV). https://www.tlv.se/in-english/in-english/. Accessed Nov 2017.

  15. Scottish Medicines Consortium (SMC). https://www.scottishmedicines.org.uk/. Accessed Nov 2017.

  16. NICE TA178. Bevacizumab (first-line), sorafenib (firstand second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. 2009. https://www.nice.org.uk/guidance/ta178/resources/bevacizumab-firstline-sorafenib-first-and-secondline-sunitinib-secondline-and-temsirolimus-firstline-for-the-treatment-of-advanced-andor-metastatic-renal-cell-carcinoma-pdf-82598442394309. Accessed Nov 2017.

  17. Therapeutic Goods Administration. AusPAR Attachment 1: Product Information for Bevacizumab. 2017. https://search.tga.gov.au/s/search.html?collection=tga-websites-web&query=bevacizumab+renal+cell. Accessed Nov 2017.

  18. Roche Ltd. Availability of new, innovative and specialist cancer drugs in Australia - Submission to the Senate Community Affairs References Committee 2015. http://www.roche-australia.com/content/dam/roche_australia/en_AU/policy/2015-02%20Senate%20Inquiry.pdf. Accessed Nov 2017.

  19. Haute Autorité de Santé. Transparency Commission: Proleukin. 2014. http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-10/proleukin_version_anglaise_ct13702.pdf. Accessed Nov 2017.

  20. PBAC. Public Summary Document: Sunitinib. 2008. http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2008-07/Sunitinib__Final_PSD_7-9_Pfizer.pdf;jsessionid=kon95ccgxtmk11uqjsi8cvyly/. Accessed Nov 2017.

  21. NICE TA169. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. 2009. https://www.nice.org.uk/guidance/ta169. Accessed Nov 2017.

  22. G-BA. Beschluss des Gemeinsamen Bundesausschusses über die Einleitung eines Stellungnahmeverfahrens zur Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XI - Besondere Arzneimittel Besondere Arzneimittel nach § 73d SGB V bei der Behandlung des metastasierten und/oder fortgeschrittenen Nierenzellkarzinoms: Bevacizumab, Sorafenib, Sunitinib, Temsirolimus. 2009. https://www.g-ba.de/downloads/39-261-879/2009-09-17-AMR13-SN-Nierenzellkarzinom.pdf. Accessed Nov 2017.

  23. Läkemedelsförmånsnämnden LÄKEMEDELSFÖRMÅNSNÄMNDENS BESLUT 2006. LÄKEMEDELSFÖRMÅNSNÄMNDENS BESLUT. Accessed June 2017.

  24. SMC. sunitinib 12.5mg, 25mg, 50mg capsules (Sutent). 2007. https://www.scottishmedicines.org.uk/SMC_Advice/Advice/384_07_sunitinib_capsules__Sutent_/sunitinib_12.5mg__25mg__50mg_capsules__Sutent_.

  25. CADTH. CEDAC Final recommendation on reconsideration and reasons for recommendation-sunitinib maleate-sutent re-submission. 2007. https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Sutent_e_April-26-2007%20.pdf. Accessed Nov 2017.

  26. Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. Value Health. 2010;13(1):55–60. https://doi.org/10.1111/j.1524-4733.2009.00616.x.

    Article  PubMed  Google Scholar 

  27. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34. https://doi.org/10.1056/NEJMoa060655.

    Article  CAS  PubMed  Google Scholar 

  28. PBS. Sorafenib, tablet, 200 mg (as tosylate), Nexavar®. 2012. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-11/sorafenib. Accessed Nov 2017.

  29. CADTH. CEDAC Final Recommendation on Reconsideration and Reasons for Recommendation - Sorafenib (Nexavar). 2007. https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Nexavar_Fe-28-07.pdf. Accessed Nov 2017.

  30. SMC. Sorafenib 200mg tablets (Nexavar) No.321/06). 2006. https://www.scottishmedicines.org.uk/files/sorafenib_200mg_tablets_Nexavar_321_06.pdf. Accessed Nov 2017.

  31. PBS. Temsirolimus, injection set containing 1 vial of powder for IV infusion 25 mg and 1 vial diluent, Torisel®. 2008. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2008-07/pbac-psd-temsirolimus-july08. Accessed Nov 2017.

  32. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.

    Article  CAS  PubMed  Google Scholar 

  33. HAS. Transparency Committee: TORISEL (CIP: 571 783-7). 2008. https://www.has-sante.fr/portail/upload/docs/application/pdf/2010-12/torisel_ct_5270.pdf. Accessed Nov 2017.

  34. Buti S, Leonetti A, Dallatomasina A, Bersanelli M. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evid. 2016;11:23–36. https://doi.org/10.2147/CE.S98687.

    Article  PubMed  PubMed Central  Google Scholar 

  35. PBS. EVEROLIMUS, tablets, 5 mg and 10 mg, Afinitor®, Novartis Pharmaceuticals Australia Pty Ltd. 2014. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-03/everolimus-rcc.

  36. HAS. Transparency Committee: AFINITOR (everolimus). 2010. http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-12/afinitor_ct_7009.pdf. Accessed Nov 2017.

  37. G-BA. Beschluss des Gemeinsamen Bundesausschusses über die Einleitung eines Stellungnahmeverfahrens zur Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XI—Besondere Arzneimittel Besondere Arzneimittel nach § 73d SGB V bei der Behandlung des metastasierten und/oder fortgeschrittenen Nierenzellkarzinoms: Everolimus. 2009. https://www.g-ba.de/downloads/39-261-1054/2009-12-17-AMR11-SN-Everolimus.pdf. Accessed Nov 2017.

  38. SMC. Re-Submission: everolimus 2.5 mg, 5 mg and 10 mg tablets (Afinitor®) SMC No. (595/10) 2014. https://www.scottishmedicines.org.uk/files/advice/everolimus_Afintor_Resubmission_FINAL_Oct_2014_Updated_30.10.14_for_website.pdf. Accessed Nov 2017.

  39. TLV. SAKEN Ansökan inom läkemedelsförmånerna. BESLUT. Afinitor. 2010. https://www.tlv.se/upload/beslut_2010/bes100907-afinitor.pdf. Accessed Nov 2017.

  40. NICE TA432. Everolimus for advanced renal cell carcinoma after previous treatment. 2017. https://www.nice.org.uk/guidance/ta432. Accessed Nov 2017.

  41. CADTH. Drugs reviewed under the Joint Oncology Drug Review Process from 2007 to 2011. 2014. https://www.cadth.ca/sites/default/files/pcodr/pcodr-ijodr-drugs-provfund.pdf. Accessed Nov 2017.

  42. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010;116(18):4256–65. https://doi.org/10.1002/cncr.25219.

    Article  CAS  PubMed  Google Scholar 

  43. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31. https://doi.org/10.1056/NEJMoa1303989.

    Article  CAS  PubMed  Google Scholar 

  44. Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC)-Final Recommendation-Pazopanib in metastatic renal cell carcinoma. 2013. https://www.cadth.ca/sites/default/files/pcodr/pcodr-votrientmrccre-fn-rec.pdf. Accessed Nov 2017.

  45. NICE TA215. Pazopanib for the first-line treatment of advanced renal cell carcinoma. 2013. https://www.nice.org.uk/guidance/ta215. Accessed Nov 2017.

  46. HAS. Commission de la Transparence - Votrient. 2015. http://www.has-sante.fr/portail/upload/docs/evamed/CT-13937_VOTRIENT_PIC_REEV_AvisPostAud_CT13937.pdf. Accessed Nov 2017.

  47. TLV. Beslut-Votrient. 2013. http://www.tlv.se/Upload/Beslut_2013/bes131212-votrient.pdf. Accessed Nov 2017.

  48. SMC. Pazopanib 200 mg, 400 mg film-coated tablets (Votrient®) SMC No.(676/11). 2011. https://www.scottishmedicines.org.uk/files/advice/pazopanib_Votrient_FINAL_February_2011.doc_for_website.pdf. Accessed Nov 2017.

  49. PBS. Pazopanib, tablet, 200 mg and 400 mg (as hydrochloride), Votrient®—March 2012. 2012. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-03/pazopanib. Accessed 30 June 2017.

  50. Gross-Goupil M, Francois L, Quivy A, Ravaud A. Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol. 2013;7:269–77. https://doi.org/10.4137/CMO.S10594.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–9. https://doi.org/10.1016/S0140-6736(11)61613-9.

    Article  CAS  PubMed  Google Scholar 

  52. Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(8):760–7. https://doi.org/10.1200/jco.2013.50.3961.

    Article  CAS  PubMed  Google Scholar 

  53. Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC) Final recommendation-axitinib. 2013. https://www.cadth.ca/sites/default/files/pcodr/pcodr-inlytamrcc-fn-rec.pdf. Accessed Nov 2017.

  54. NICE TA333. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment. 2015. https://www.nice.org.uk/guidance/ta333. Accessed Nov 2017.

  55. HAS. Commission de la Transparence - INLYTA. 2013. http://www.has-sante.fr/portail/upload/docs/evamed/CT-12556_INLYTA%20Ins%20Avis%202_CT%2012556.pdf. Accessed Nov 2017.

  56. IQWiG. Axitinib – Benefit assessment according to § 35a Social Code Book V1. 2012. https://www.iqwig.de/download/A12-14_Axitinib_Extract_of_dossier_assessment.pdf. Accessed Nov 2017.

  57. TLV. Inlyta ingår i högkostnadsskyddet. 2013. https://www.tlv.se/beslut/beslut-lakemedel/generell-subvention/inlyta-ingar-i-hogkostnadsskyddet/. Accessed Nov 2017.

  58. SMC. Axitinib (Inlyta). 2013. https://www.scottishmedicines.org.uk/SMC_Advice/Advice/855_13_axitinib_Inlyta/axitinib_Inlyta_Resubmission. Accessed Nov 2017.

  59. PBS. Axitinib, tablet, 1 mg and 5 mg, Inlyta® - Nov 2013. 2013. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-11/axitinib. Accessed Nov 2017.

  60. PBAC. AXITINIB tablets, 1 mg & 5 mg; Inlyta®; Pfizer Australia Pty Ltd. 2014. http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2014-11/files/axitinib-psd-11-2014.pdf. Accessed Nov 2017.

  61. Sarfaty M, Leshno M, Gordon N, et al. Cost effectiveness of nivolumab in advanced renal cell carcinoma. Eur Urol. 2017;15:8. https://doi.org/10.1016/j.eururo.2017.07.041.

    Article  Google Scholar 

  62. Venur VA, Joshi M, Nepple KG, Zakharia Y. Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Dev Ther. 2017;11:1175–82. https://doi.org/10.2147/DDDT.S110209.

    Article  CAS  Google Scholar 

  63. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. https://doi.org/10.1056/NEJMoa1510665.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. pCODR. pan-Canadian Oncology Drug Review. Final economic guidance report. Nivolumab (Opdivo) for metastatic renal cell carcinoma. 2016. https://www.cadth.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_fn_egr.pdf. Accessed Nov 2017.

  65. NICE TA417. Nivolumab for previously treated advanced renal cell carcinoma. 2016. https://www.nice.org.uk/guidance/ta417/chapter/4-Committee-discussion#clinical-effectiveness. Accessed Nov 2017.

  66. HAS. Commission de la Transparence. Avis: nivolumab. 2016. http://www.has-sante.fr/portail/upload/docs/evamed/CT-15277_OPDIVO_cancer_rein_PIC_INS_Avis2_CT15277.pdf. Accessed Nov 2017.

  67. IQWiG. IQWiG Reports—Commission No. A16-24. Nivolumab (renal cell carcinoma)-benefit assessment according to §35a Social Code Book V1. 2016. https://www.iqwig.de/download/A16-24_Nivolumab_Extract-of-dossier-assessment.pdf. Accessed Nov 2017.

  68. PBAC. Nov 2016 PBAC outcomes—subsequent decisions not to recommend. 2016. https://engonetuf.blob.core.windows.net/assets/uploads/files/subsequent-decisions-not-to-recommend-2016-11.pdf. Accessed Nov 2017.

  69. PBAC. NIVOLUMAB, Opdivo®, Bristol-Myers Squibb Australia Pty Ltd. (PDF on file). 2017.

  70. SMC. Nivolumab (Opdivo). 2017. https://www.scottishmedicines.org.uk/SMC_Advice/Advice/1188_16_nivolumab_Opdivo_for_renal_cell_carcinoma/nivolumab_Opdivo_Resubmission. Accessed Nov 2017.

  71. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–308. https://doi.org/10.1158/1535-7163.MCT-11-0264.

    Article  CAS  PubMed  Google Scholar 

  72. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–27. https://doi.org/10.1016/S1470-2045(16)30107-3.

    Article  CAS  PubMed  Google Scholar 

  73. HAS. Commission de la Transparence: Cabozantinib. 2017. http://www.has-sante.fr/portail/upload/docs/evamed/CT-15738_CABOMETYX_PIC_INS_AvisPostObs_CT15738.pdf. Accessed Nov 2017.

  74. IQWiG. [A16-69] Cabozantinib (renal cell carcinoma)—benefit assessment according to §35a Social Code Book V. 2016. https://www.iqwig.de/en/projects-results/projects/drug-assessment/a16-69-cabozantinib-renal-cell-carcinoma-benefit-assessment-according-to-35a-social-code-book-v.7687.html. Accessed Nov 2017.

  75. Tourani JM, Lucas V, Mayeur D, et al. Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial. Ann Oncol. 1996;7(5):525–8.

    Article  CAS  PubMed  Google Scholar 

  76. Fund CD. https://www.england.nhs.uk/cancer/cdf/. Accessed Nov 2017.

Download references

Acknowledgements

Funding

This research and associated article processing charges were sponsored by Eisai, Inc. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Medical Writing Assistance

Medical writing services, provided by Carina Schey from Global Market Access Solutions, were funded by Eisai.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authorship Contributions

Carina Schey was involved in the data extraction and analysis and drafted the manuscript. All authors approved the final manuscript.

Disclosures

Carina Schey was contracted and paid by Eisai to conduct the research. Genevieve Meier is an employee of Eisai. Janice Pan is an employee of Eisai. There are no other relevant competing or conflicts of interests from any of the authors.

Compliance with Ethics Guidelines

This article does not contain any studies with human participants or animals performed by any of the authors; therefore ethics approval was not required.

Data Availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author information

Authors and Affiliations

  1. Global Market Access Solutions, Geneva, Switzerland

    Carina Schey

  2. Unit of PharmacoEpidemiology and PharmacoEconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands

    Carina Schey

  3. Eisai Co. Ltd., Woodcliff Lake, NJ, USA

    Genevieve Meier & Janice Pan

Authors
  1. Carina Schey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Genevieve Meier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Janice Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carina Schey.

Additional information

Enhanced digital features

To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7901441.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schey, C., Meier, G. & Pan, J. Metastatic Renal Cell Cancer: An Analysis of Reimbursement Decisions. Adv Ther 36, 1266–1278 (2019). https://doi.org/10.1007/s12325-019-00947-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-019-00947-0

Keywords

  • Health technology assessment
  • Metastatic renal cell carcinoma
  • Reimbursement